To Evaluate the Efficacy and Safety of LuminoMark Injection in Patients With Nonpalpable Breast Lesions(Phase 3)

• Status: Completed
• Trial end date: 2021-01-28
• Target enrollment: 0
• Participant gender: All

Summary

This study is a multicenter, Randomized, Open-label, Parallel, Phase 3 Clinical Trial in 8 weeks for screening, once Investigational product injection, Follow up visit.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hanlim Pharm. Co., Ltd.

Criteria

Inclusion Criteria:

1. 19 years ≤ age ≥ 80 years

2. Those who have lesion vial mammography and breast ultrasound

3. Those who be expected to do operation about non palpable breast lesion excision

4. Written consent voluntarily to participate in this clinical trial

Exclusion Criteria:

1. Patients who be expected to do mastectomy

2. Patients with multiple tumor or diffuse microcalcification

3. Patients who have ink on invasive cancer or ductal carcinoma in situ despite 3 times local resection

4. Patients who were treated with moderate to severe radiotherapy

5. Patients who were treated with neoadjuvant Chemotherapy

6. Patients with active invading skin connective tissue disease

7. Patients with local progressing breast cancer or inflammatory local progressing breast cancer

8. Patients who have an allergy to investigational product or any of the component with the Investigational product

9. Patients who disagree about contraception for this clinical trial

10. A pregnant women or lactating women

11. Patients who participated in other clinical trials within the past 12 weeks from the date of informed consent

12. Patients who investigators determines unsuitable for this clinical trial